The telehealth company has been selling a copycat version of a popular obesity drug during the recent shortage.

Shares tumbled 21% to $52.22. Over the last year, the stock has surged more than 450%.

Hims & Hers Health Inc. has acquired a California-based manufacturing facility to expand its range of peptide treatments, ...

Hims & Hers' acquisition of Trybe Labs broadens its treatment range and enhances its competitive edge through increased data ...

It may be early, but some blazing investments have already delivered wealth-altering gains in this young year.

Our editors handpick the products that we feature. We may earn commission from the links on this page. Hair texture changes during menopause and perimenopause are real—and often exasperating.

Hims & Hers wants to keep on selling a compounded version of Ozempic. And it's channeling anti-establishment vibes to make its case.

The Hims brand has primed people to view both their everyday health and the natural-aging processes as problems that can be ...

Hims & Hers offers a copycat of the blockbuster weight-loss drug at a fraction of the cost. But it might be a short-lived ...